Skip to Content

Achilles Therapeutics PLC ADR ACHL

Morningstar Rating
$0.78 0.00 (0.35%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

ACHL is trading at a 71% discount.
Price
$0.78
Fair Value
$9.88
Uncertainty
Extreme
1-Star Price
$63.72
5-Star Price
$9.81
Economic Moat
Zyy
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ACHL is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$0.78
Day Range
$0.760.81
52-Week Range
$0.741.76
Bid/Ask
$0.76 / $0.83
Market Cap
$32.52 Mil
Volume/Avg
119,428 / 784,703

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Achilles Therapeutics PLC is a biopharmaceutical company. It is developing AI-powered precision T-cell therapies targeting clonal neoantigens to treat solid tumors. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Total Number of Employees
215

Valuation

Metric
ACHL
Price/Earnings (Normalized)
Price/Book Value
0.23
Price/Sales
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
ACHL
Quick Ratio
8.35
Current Ratio
8.57
Interest Coverage
Quick Ratio
ACHL

Profitability

Metric
ACHL
Return on Assets (Normalized)
−33.50%
Return on Equity (Normalized)
−37.89%
Return on Invested Capital (Normalized)
−36.29%
Return on Assets
ACHL
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRLzxyyzrqhNcwcl$557.8 Bil
VRTX
Vertex Pharmaceuticals IncGxhsrjlmHwkgj$104.7 Bil
REGN
Regeneron Pharmaceuticals IncLqhqsrqsWlfzj$99.6 Bil
MRNA
Moderna IncNbcgjcxSgmp$38.8 Bil
ARGX
argenx SE ADRFbxvykktSwxf$21.4 Bil
BNTX
BioNTech SE ADRVtvjsmvWwf$21.3 Bil
ALNY
Alnylam Pharmaceuticals IncBmsdhhpbVjdbzk$18.4 Bil
BMRN
Biomarin Pharmaceutical IncYvrclwmzVdlpfw$17.5 Bil
RPRX
Royalty Pharma PLC Class APlhprwjmqClvlpp$12.4 Bil
INCY
Incyte CorpFmnrvplcfKtszht$11.9 Bil

Sponsor Center